Search Results - "DORFLINGER, E"

Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment by Goetz, C G, Stebbins, G T, Shale, H M, Lang, A E, Chernik, D A, Chmura, T A, Ahlskog, J E, Dorflinger, E E

“…Although dyskinesia is a frequent and important problem in Parkinson's disease (PD), a reliable assessment measure has not been thoroughly developed and…”
Get more information

Tolcapone improves motor function in parkinsonian patients with the wearing-off phenomenon: A double-blind, placebo-controlled, multicenter trial by RAJPUT, A. H, MARTIN, W, SAINT-HILAIRE, M.-H, DORFLINGER, E, PEDDER, S

“…We studied the new catechol-O-methyltransferase inhibitor tolcapone, 100 and 200 mg, three times daily (tid) in a randomized, double-blind, parallel-group…”
Get full text

P.3.e.009 Glycine reuptake inhibitor RG1678: results of the proof-of-concept study for the treatment of negative symptoms in schizophrenia by Umbricht, D, Martin-Facklam, M, Youssef, E, Yoo, K, Dorflinger, E, Bausch, A, Alberati, D, Santarelli, L

Get full text

Tolcapone in stable Parkinson's disease : Efficacy and safety of long-term treatment by WATERS, C. H, KURTH, M, BAILEY, P, SHULMAN, L. M, LEWITT, P, DORFLINGER, E, DEPTULA, D, PEDDER, S

Get full text

A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients by Hauser, Robert A., Molho, Eric, Shale, Heidi, Pedder, Simon, Dorflinger, Ernest E.

“…Tolcapone is a potent, reversible catechol‐O‐methyltransferase (COMT) inhibitor with both peripheral and central activity. It has been demonstrated to improve…”
Get full text

Tolcapone Improves Motor Function and Reduces Levodopa Requirement in Patients with Parkinson's Disease Experiencing Motor Fluctuations: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial by Kurth, M. C., Adler, C. H., St. Hilaire, M., Singer, C., Waters, C., LeWitt, P., Chernik, D. A., Dorflinger, E. E., Yoo, K.

Get full text

Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial by Rajput, A H, Martin, W, Saint-Hilaire, M H, Dorflinger, E, Pedder, S

“…We studied the new catechol-O-methyltransferase inhibitor tolcapone, 100 and 200 mg, three times daily (tid) in a randomized, double-blind, parallel-group…”
Get full text

Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson's disease : the degree and reversibility of human brain MAO B inhibition by Ro 19 6327 by FOWLER, J. S, VOLKOW, N. D, DORFLINGER, E, YOO, K, MORAWSKY, L, FAZZINI, E, LOGAN, J, SCHLYER, D. J, MACGREGOR, R. R, WANG, G.-J, PAPPAS, N, ALEXOFF, D, SHEA, C, GATLEY, S. J

“…The possibility of slowing the progression of Parkinson's disease (PD) with inhibitors of monoamine oxidase B (MAO B) has stimulated the development of new MAO…”
Get full text

Diffusion-Weighted MR Imaging of Intramedullary Spinal Cord Abscess by DÖRFLINGER-HEJLEK, E, KIRSCH, E. C, REITER, H, OPRAVIL, M, KAIM, A. H

“…Early diagnosis and prompt initiation of adequate treatment are essential for clinical outcome in ISCA. We report a case in which DWI provided a more specific…”
Get full text

Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity by ACUNA, Gonzalo, FOERNZLER, Dorothee, ZUNG TO, THOMPSON, Annick, JIA LI, HASHIMOTO, Lara, LINDPAINTNER, Klaus, LEONG, Diane, RABBIA, Michael, SMIT, Ralf, DORFLINGER, Ernest, GASSER, Rodolfo, HOH, Josephine, OTT, Jürg, BORRONI, Edilio

“…A retrospective pharmacogenetic study was conducted to identify possible genetic susceptibility factors in patients in whom the administration of the…”
Get full text

A physical chemistry experiment in Mossbauer spectroscopy by Armstrong, William H, Dorflinger, Ernest E, Anderson, Owen T, Willeford, Bennett R

“…This article includes relevant theory and a detailed procedure for the physical chemistry experiment in Mossbauer spectroscopy…”
Get full text

COMT inhibition and Parkinson's disease by Dorflinger, E., Magni, G., Hoffmann, F.

Get full text

Illness impact and adjustment to Parkinson's disease: Before and after treatment with tolcapone by Welsh, Mickie D., Dorflinger, Ernest, Chernik, Doris, Waters, Cheryl

“…Research on the impact of disease and treatment on health status and quality of life in patients with movement disorders is limited. We studied quality of life…”
Get full text

Slow recovery of human brain MAO B after L-deprenyl (Selegeline) withdrawal by Fowler, J S, Volkow, N D, Logan, J, Wang, G J, MacGregor, R R, Schyler, D, Wolf, A P, Pappas, N, Alexoff, D, Shea, C

“…L-Deprenyl (Selegeline) is an enzyme-activated irreversible inhibitor of monoamine oxidase B (MAO B; EC 1.4.3.4). It is used to treat Parkinson's disease at a…”
Get more information

Tolcapone added to levodopa in stable parkinsonian patients: A double-blind placebo-controlled study by Dupont, Erik, Burgunder, Jean-Marc, Findley, Leslie J., Olsson, Jan-Edvin, Dorflinger, Ernest

“…The primary objective of this study was to assess the effect of tolcapone on levodopa dosage in parkinsonian patients whose “wearing‐off” phenomenon has been…”
Get full text

Tolcapone in stable Parkinson's disease: Efficacy and safety of long-term treatment by Waters, C. H., Kurth, M., Bailey, P., Shulman, L. M., LeWitt, P., Dorflinger, E., Deptula, D., Pedder, S.

Get full text

A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Tolcapone De Novo Study Group by Hauser, R A, Molho, E, Shale, H, Pedder, S, Dorflinger, E E

“…Tolcapone is a potent, reversible catechol-O-methyltransferase (COMT) inhibitor with both peripheral and central activity. It has been demonstrated to improve…”
Get full text

Tolcapone improves motor function in parkinsonian patients with the wearing-off phenomenon : A double-blind, placebo-controlled, multicenter trial: Tolcapone: COMT inhibition for the treatment of Parkinson's disease by RAJPUT, A. H, MARTIN, W, SAINT-HILAIRE, M.-H, DORFLINGER, E, PEDDER, S

Get full text

Tolcapone added to levodopa in stable parkinsonian patients: a double-blind placebo-controlled study. Tolcapone in Parkinson's Disease Study Group II (TIPS II) by Dupont, E, Burgunder, J M, Findley, L J, Olsson, J E, Dorflinger, E

“…The primary objective of this study was to assess the effect of tolcapone on levodopa dosage in parkinsonian patients whose "wearing-off" phenomenon has been…”
Get full text

Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Tolcapone Stable Study Group by Waters, C H, Kurth, M, Bailey, P, Shulman, L M, LeWitt, P, Dorflinger, E, Deptula, D, Pedder, S

“…In this double-blind, placebo-controlled trial, we investigated the effect of the catechol-O-methyltransferase inhibitor tolcapone 100 or 200 mg three times…”
Get full text